Valuation: GRER CANNPAR

Market Cap 398K 344K 326K 295K 553K 38.14M 557K 3.89M 1.49M 19.34M 1.49M 1.46M 61.67M P/E 2024
-1.8x
P/E 2025 -0.19x
Enterprise Value 660K 572K 541K 490K 919K 63.34M 926K 6.45M 2.48M 32.12M 2.48M 2.43M 102M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day+8.05%
1 week+14.23%
Current month+73.83%
1 month+73.75%
3 months+142.17%
6 months+247.65%
Current year+433.07%
1 week 0.37
Extreme 0.37
0.4
1 month 0.15
Extreme 0.1521
0.4
Current year 0.06
Extreme 0.0631
0.67
1 year 0.04
Extreme 0.036
0.67
3 years 0.04
Extreme 0.036
3.6
5 years 0.04
Extreme 0.036
11.25
10 years 0.04
Extreme 0.036
1,102.44
Manager TitleAgeSince
Chief Executive Officer 39 29/06/2026
Director of Finance/CFO - 29/07/2026
Chief Operating Officer 73 29/07/2026
Director TitleAgeSince
Chairman 39 29/06/2026

Financials

2024 2025
Net sales - -
Net income -179K -155K -147K -133K -249K -17.17M -251K -1.75M -673K -8.71M -673K -658K -27.77M -332K -287K -272K -246K -462K -31.81M -465K -3.24M -1.25M -16.13M -1.25M -1.22M -51.44M
Net Debt 374K 324K 306K 277K 521K 35.88M 525K 3.66M 1.41M 18.19M 1.41M 1.37M 58.02M 263K 228K 215K 195K 366K 25.21M 368K 2.57M 988K 12.78M 987K 965K 40.76M
Logo GRER CANNPAR
The Greater Cannabis Company, Inc. is a biotechnology company. The Company is involved in additional research and development of cannabinoid-based therapeutics that reduce disruptive symptoms in patients suffering from neuropsychiatric disorders. The Company also focuses on developing new formulations around cannabinoid therapeutics. Its wholly owned subsidiary is Biocanrx, Inc.
Employees
1
Sector
-
Date Price Change Volume
15/09/26 $0.3998 +8.05% 30,302
09/09/26 $0.3700 +5.71% 909
  1. Stock Market
  2. Stocks
  3. GCAN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!